Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.


Options:
A: List of Inclusion and Exclusion Criteria:

Inclusion Criteria:

* Type 2 Diabetes Mellitus patients on metformin monotherapy
* 7% ≤ HbA1c ≤ 12%
* 20 kg/m² ≤BMI ≤ 35 kg/m²
* Diabetes duration: at least 6 months

Exclusion Criteria:

* Type 1 Diabetes Mellitus patients
* Clinical evidence of active liver disease, or serum Alanine AminoTransferase 3 times the upper limit of the normal range
* Serum creatinine: 1.5 mg/dl for males, 1.4 mg/dl for females
* Acute and chronic metabolic acidosis, including diabetic ketoacidosis
* History of alcohol or other substance abuse
* Pregnancy or not using contraceptive in childbearing aged women
* Known hypersensitivity to Lantus, SU or metformin
* Any disease or condition that in the opinion of the investigator may interfere with completion of the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
B: Inclusion Criteria:

* All patients must have a diagnosis of T2DM and may be currently treated with a stable regimen of antihyperglycemic agent(s)
* Patients in the study must have a HbA1c between \>=7 and \<=10.0%
* Patients must have a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)

Exclusion Criteria:

* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
C: Inclusion Criteria:

* Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening
* HbA1c \>or = 7% and \< or = 10%
* Fasting c-peptide \> or = 1.0 umol
* Body Mass Index \< or = 41 kg/m2
* Mean serum triglycerides \< or = 600 mg/dl
D: Inclusion Criteria:

* Type 2 diabetes
* Stable treatment with Oral Anti-Diabetic Drugs (metformin, sulphonylurea or a combination of both) for at least 3 months at the discretion of the Investigator
* HbA1C equal to or greater than 7.0% and equal to or lower than 11.0%
* Body Mass Index (BMI) equal to or lower than 45.0 kg/m2

Exclusion Criteria:

* Previous treatment with insulin
* Treatment with any anti-diabetic drug other than metformin and sulphonylurea
* Any previous exposure to exenatide or liraglutide
* Impaired liver or/and renal function
* History of any significant cardiac events
* Known retinopathy or maculopathy requiring acute treatment
* Recurrent major hypoglycaemia or hypoglycaemic unawareness

Answer: B